Jiangsu Sihuan Bioengineering Co., Ltd (SHE:000518)

China flag China · Delayed Price · Currency is CNY
3.070
+0.010 (0.33%)
May 13, 2026, 3:04 PM CST
Market Cap3.16B +42.8%
Revenue (ttm)381.71M +99.9%
Net Income-32.49M
EPS-0.03
Shares Out1.03B
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume17,363,583
Average Volume14,928,791
Open3.020
Previous Close3.060
Day's Range3.000 - 3.100
52-Week Range1.970 - 3.180
Beta0.22
RSI60.14
Earnings DateApr 18, 2026

About SHE:000518

Jiangsu Sihuan Bioengineering Co., Ltd., together with its subsidiaries, engages in the production and sales of biopharmaceutical products in China and internationally. The company offers Delusen and New Delusen, a human interleukin-2 for injection are immunomodulators used for the biotherapy of tumors and treatment of patients with weakened immune function; Xinlisheng, a human granulocyte colony-stimulating factor injection used to treat neutropenia caused by bone marrow transplantation, cancer chemotherapy, myelodysplastic syndrome, and aplas... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1992
Employees 277
Stock Exchange Shenzhen Stock Exchange
Ticker Symbol 000518
Full Company Profile

Financial Performance

In 2025, SHE:000518's revenue was 344.38 million, an increase of 69.22% compared to the previous year's 203.52 million. Losses were -37.09 million, -66.28% less than in 2024.

Financial Statements